NCT02330991View on ClinicalTrials.gov

A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

September 30, 2020

Conditions
Glioblastoma
Interventions
DRUG

Temozolomide

All Listed Sponsors
lead

Beijing Sanbo Brain Hospital

OTHER

NCT02330991 - A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | Biotech Hunter | Biotech Hunter